These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9014749)

  • 1. A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity.
    Byrne DS; McKay AJ; Blackie R; MacKie RM
    Eur J Cancer; 1996 Nov; 32A(12):2082-7. PubMed ID: 9014749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
    Cheng TY; Grubbs E; Abdul-Wahab O; Leu SY; Hung CF; Petros W; Aloia T; Fedrau R; Pruitt S; Colvin M; Friedman H; Tyler D
    Am J Surg; 2003 Nov; 186(5):460-7. PubMed ID: 14599607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Melphalan pharmacokinetics during isolated limb regional perfusion in patients with skin melanoma and soft tissue sarcoma].
    Gafton GI; Senchik KY; Petrov VG; V V Semiglazov ; N V Tatyanicheva ; V G Bespalov ; Semiletova YV; Gafton IG; Zinoviev GV; Kireeva GS
    Vopr Onkol; 2015; 61(6):932-6. PubMed ID: 26995981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion for melanoma.
    Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
    J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
    [No Abstract]   [Full Text] [Related]  

  • 5. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?
    Huismans AM; Kroon HM; Haydu LE; Kam PC; Thompson JF
    Ann Surg Oncol; 2012 Sep; 19(9):3050-6. PubMed ID: 22526898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
    Papadia F; Basso V; Patuzzo R; Maurichi A; Di Florio A; Zardi L; Ventura E; González-Iglesias R; Lovato V; Giovannoni L; Tasciotti A; Neri D; Santinami M; Menssen HD; De Cian F
    J Surg Oncol; 2013 Feb; 107(2):173-9. PubMed ID: 22674435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
    Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H
    Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion with melphalan for melanoma.
    Nieweg OE; Kroon BB
    J Surg Oncol; 2014 Mar; 109(4):332-7. PubMed ID: 24421252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of acute regional toxicity following isolated limb perfusion for melanoma.
    Thompson JF; Eksborg S; Kam PC; Ingvar C; Yau DF; Lai DT; Ramzan I
    Melanoma Res; 1996 Jun; 6(3):267-71. PubMed ID: 8819130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb.
    Wu ZY; Smithers BM; Roberts MS
    Melanoma Res; 1997 Jun; 7(3):252-64. PubMed ID: 9195565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
    Pace M; Gattai R; Mascitelli EM; Millanta L
    J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
    Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
    Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity.
    Duprat Neto JP; Oliveira F; Bertolli E; Molina AS; Nishinari K; Facure L; Fregnani JH
    Clinics (Sao Paulo); 2012; 67(3):237-41. PubMed ID: 22473404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.
    Kroon HM; Coventry BJ; Henderson MA; Barbour A; Serpell J; Smithers BM; Thompson JF
    Eur J Surg Oncol; 2019 May; 45(5):832-837. PubMed ID: 30867095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.